Ignite Creation Date:
2024-05-06 @ 4:29 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05005442
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-09-01
First Post:
2021-08-12
Brief Title:
A Study of PembrolizumabVibostolimab MK-7684A in RelapsedRefractory Hematological Malignancies MK-7684A-004 KEYVIBE-004
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC